Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Dimitrov

Showing results (401-410 of 442) with videos related to

Pageof 45
Sort By:
Biomaterials|December 20, 2014
Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulationsPavan Puligujja, Shantanu S Balkundi, Lindsey M Kendrick, et al.
Nature Structural & Molecular Biology|April 30, 2021
Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteinsHa V Dang, Robert W Cross, Viktoriya Borisevich, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 30, 2000
Impact of HIV-1 infection and highly active antiretroviral therapy on the kinetics of CD4+ and CD8+ T cell turnover in HIV-infected patientsR A Lempicki, J A Kovacs, M W Baseler, et al.
Cancer Cell|August 30, 2020
Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based ImmunotherapiesJingwen Si, Xiangjun Shi, Shuhao Sun, et al.
Journal of Virology|August 4, 2019
Rapid Elimination of Broadly Neutralizing Antibodies Correlates with Treatment Failure in the Acute Phase of Simian-Human Immunodeficiency Virus InfectionYanling Wu, Jing Xue, Chunyu Wang, et al.
Journal of Virology|September 13, 2003
Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1Aran F Labrijn, Pascal Poignard, Aarti Raja, et al.
Science Translational Medicine|September 10, 2020
Enhancing KDM5A and TLR activity improves the response to immune checkpoint blockadeLiangliang Wang, Yan Gao, Gao Zhang, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 11, 2007
Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodiesZhongyu Zhu, Samitabh Chakraborti, Yuxian He, et al.
Cell Reports. Medicine|August 2, 2021
A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitopeSwetha Raman, Samantha N Buongervino, Maria V Lane, et al.
The Journal of Clinical Investigation|June 5, 2018
Tumor stroma-targeted antibody-drug conjugate triggers localized anticancer drug releaseChristopher Szot, Saurabh Saha, Xiaoyan M Zhang, et al.
Pageof 45

Showing results (401-410 of 442) with videos related to

Sort By:
Pageof 45
Biomaterials|December 20, 2014
Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulationsPavan Puligujja, Shantanu S Balkundi, Lindsey M Kendrick, et al.
Nature Structural & Molecular Biology|April 30, 2021
Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteinsHa V Dang, Robert W Cross, Viktoriya Borisevich, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 30, 2000
Impact of HIV-1 infection and highly active antiretroviral therapy on the kinetics of CD4+ and CD8+ T cell turnover in HIV-infected patientsR A Lempicki, J A Kovacs, M W Baseler, et al.
Cancer Cell|August 30, 2020
Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based ImmunotherapiesJingwen Si, Xiangjun Shi, Shuhao Sun, et al.
Journal of Virology|August 4, 2019
Rapid Elimination of Broadly Neutralizing Antibodies Correlates with Treatment Failure in the Acute Phase of Simian-Human Immunodeficiency Virus InfectionYanling Wu, Jing Xue, Chunyu Wang, et al.
Journal of Virology|September 13, 2003
Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1Aran F Labrijn, Pascal Poignard, Aarti Raja, et al.
Science Translational Medicine|September 10, 2020
Enhancing KDM5A and TLR activity improves the response to immune checkpoint blockadeLiangliang Wang, Yan Gao, Gao Zhang, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 11, 2007
Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodiesZhongyu Zhu, Samitabh Chakraborti, Yuxian He, et al.
Cell Reports. Medicine|August 2, 2021
A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitopeSwetha Raman, Samantha N Buongervino, Maria V Lane, et al.
The Journal of Clinical Investigation|June 5, 2018
Tumor stroma-targeted antibody-drug conjugate triggers localized anticancer drug releaseChristopher Szot, Saurabh Saha, Xiaoyan M Zhang, et al.
Pageof 45